source
- FDA faces push for flexible rare-disease trial designs as commissioner's nomination withdrawnThe FDA’s weekly briefing highlighted several notable developments, including the sudden withdrawal of the Trump administration’s nominee for FDA commissioner at the last minute. The agency also a…
- ‘It’s a very healthy sector’: Biopharma gathers in London as M&A shines and China clouds loomAs the grand hotels and cosy cafes filled with biopharma executives and investors for London Life Sciences Week, the weather was as temperamental as any other English November.